Statement 27 May 2022

IFPMA and BIO Statement on Influenza Preparedness for WHA75 agenda item 17.1

By IFPMA
Downloads
Statement
Share
Topics

The WHO Global Influenza Surveillance and Response System (GISRS) celebrates this year its 70th anniversary, marking decades of successful information sharing and collaboration for influenza surveillance, preparedness and response. Its expansion to GISRS+ to include other respiratory pathogens must ensure that influenza surveillance is not deprioritized nor negatively impacted.

With regards the EB150 request for the Secretariat to continue reporting on influenza virus-sharing trends, and propose solutions to address any disruptions in virus-sharing, industry would like to request WHO and Member States that the options already being explored do truly and effectively aim at addressing the current and future seasonal virus sharing challenges, and do not unintentionally impose barriers to the development and manufacturing of seasonal influenza vaccines.

The biopharmaceutical industry remains a committed partner in effectively improving influenza seasonal and pandemic preparedness and response, and looks forward to further progress on this area.

About IFPMA

IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.

To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.

ifpma.org

Media Contact

Elliot Dunster
Top